Holen Sie sich die Stockscreener-App
25.08
10.53%
2.39
Vorhandelsmarkt:
25.44
0.36
+1.44%
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure (NASDAQ:QURE) Shares Gap UpStill a Buy? - MarketBeat
uniQure N.V. $QURE Shares Sold by SG Americas Securities LLC - MarketBeat
uniQure N.V. (QURE) Stock Analysis: Uncovering a 143.91% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Huntington's Disease Market Poised for Transformation Through - openPR.com
UNIQURE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - 富途资讯
QURE INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving uniQURE N.V. - ACCESS Newswire
Here’s Why uniQure (QURE) Fell in Q3 - Insider Monkey
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Short Interest in uniQure N.V. (NASDAQ:QURE) Rises By 33.8% - MarketBeat
(QURE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
QURE Investigation Reminder: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
uniQure (NASDAQ:QURE) Shares Up 5%Here's What Happened - MarketBeat
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - MSN
Setup Watch: Is AMPGW subject to activist investor interestEarnings Risk Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
Downgrade Watch: Will uniQure NV stock benefit from M ALong Setup & Daily Market Momentum Tracking - baoquankhu1.vn
Robert Gut Sells 25,613 Shares of uniQure (NASDAQ:QURE) Stock - MarketBeat
RSI Check: Can uniQure NV continue delivering strong returnsJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Health Check: How Prudently Does UniQure (NASDAQ:QURE) Use Debt? - 富途牛牛
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
Cantor Fitzgerald Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $55 - 富途资讯
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald By Investing.com - Investing.com Australia
uniQure stock falls after FDA feedback on gene therapy application - MSN
Ideas Watch: Does uniQure NV stock trade at a discount to peersJuly 2025 Outlook & Daily Chart Pattern Signal Reports - moha.gov.vn
How Investors Are Reacting To uniQure (QURE) After Its Pivotal FDA Type A Meeting On AMT-130 - Yahoo Finance
Assessing uniQure (QURE) Valuation After Recent Volatility And Gene Therapy Progress - Yahoo Finance
uniQure updates gene therapy pipeline and regulatory outlook - TipRanks
uniQure N.V. Updates on Gene Therapy Developments - TradingView
uniQure (NASDAQ:QURE) Director Sells $174,319.20 in Stock - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 9.2%Should You Sell? - MarketBeat
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? - Insider Monkey
uniQure Shares Skyrocket After Positive Huntington’s Disease Gene Therapy Data - MSN
uniQure (NASDAQ:QURE) Rating Lowered to Sell at Wall Street Zen - MarketBeat
uniQure N.V. Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure N.V. Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy - Investing.com Nigeria
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy - Nasdaq
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy - Investing.com
US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy - marketscreener.com
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus
uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy By Investing.com - Investing.com South Africa
uniQure prepares for FDA Type A meeting on AMT-130 - TipRanks
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy By Investing.com - Investing.com South Africa
uniQure Announces Type A Meeting Scheduled with FDA - The Manila Times
uniQure N.V. Schedules FDA Meeting for AMT-130 Approval - TradingView — Track All Markets
2.92%
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):